Gilles de la Tourette's syndrome

From Aaushi
Jump to navigation Jump to search

Introduction

(also see NINDS Tourette Syndrome Information Page)

Etiology

Epidemiology

  • rare
  • affected individuals may be of any level of intelligence
  • male:female ratio of 3:1
  • chilhood onset[1]

Genetics

  • associated with defects in IMMP2L gene
  • associated with defectes in SLITRK1 gene

Clinical manifestations

* diagnosis of Tourette's syndrome requires presence of motor & vocal tics for at least 1 year[1]

Management

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Medical Knowledge Self Assessment Program (MKSAP) 11, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  2. DSM-IV
  3. Kurlan RM. Treatment of Tourette syndrome. Neurotherapeutics. 2014 Jan;11(1):161-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24043501 Free PMC Article
  4. 4.0 4.1 4.2 Pringsheim T, Okun MS, Muller-Vahl K et al Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. May 07, 2019; 92 (19) Special Article PMID: https://www.ncbi.nlm.nih.gov/pubmed/31061208 https://n.neurology.org/content/92/19/896
    Pringsheim T, Holler-Managan Y, Okun MS et al May 07, 2019; 92 (19) Special Article Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. May 07, 2019; 92 (19) Special Article PMID: https://www.ncbi.nlm.nih.gov/pubmed/31061209 https://n.neurology.org/content/92/19/907
  5. NINDS Tourette Syndrome Information Page https://www.ninds.nih.gov/Disorders/All-Disorders/Tourette-Syndrome-Information-Page

Database